{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:23:58Z","timestamp":1793496238354,"version":"4.5.0"},"reference-count":78,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Dupuytren\u2019s disease (DD) is a common fibrotic disorder of the hand and can significantly impair hand function. Although the exact pathogenesis of this disorder remains to be elucidated, immunological, genetic and cellular factors likely interact. In this review, we summarise recent advances in the understanding of DD pathogenesis and look to the future for potential novel therapeutic targets. In addition, we discuss the therapeutic options in DD with a focus on the need for more rigorous evidence to allow a meaningful comparison of different treatment modalities.<\/ns4:p>","DOI":"10.12688\/f1000research.17779.1","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T15:45:05Z","timestamp":1551368705000},"page":"231","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Recent advances in the understanding of Dupuytren\u2019s disease"],"prefix":"10.12688","volume":"8","author":[{"given":"Thomas","family":"Layton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9579-9411","authenticated-orcid":false,"given":"Jagdeep","family":"Nanchahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"593-603","DOI":"10.1097\/01.prs.0000438455.37604.0f","article-title":"A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries.","volume":"133","author":"R Lanting","year":"2014","journal-title":"Plast Reconstr Surg."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"1014-8","DOI":"10.1016\/j.jhsa.2005.03.005","article-title":"A retrospective review of the management of Dupuytren\u2019s nodules.","volume":"30","author":"R Reilly","year":"2005","journal-title":"J Hand Surg Am."},{"key":"ref-3","doi-asserted-by":"crossref","first-page":"635-42; discussion 643","DOI":"10.1016\/S0749-0712(21)00900-8","article-title":"Diagnosis and indications for surgical treatment.","volume":"7","author":"A Smith","year":"1991","journal-title":"Hand Clin."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"31-4","DOI":"10.1080\/030097401750065292","article-title":"Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease.","volume":"30","author":"K Gudmundsson","year":"2009","journal-title":"Scand J Rheumatol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"149-58","DOI":"10.1007\/s11552-010-9306-4","article-title":"Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study.","volume":"6","author":"D Dibenedetti","year":"2011","journal-title":"Hand (N Y)."},{"key":"ref-6","first-page":"316-20","article-title":"A high prevalence of Dupuytren's disease in Flanders.","volume":"76","author":"I Degreef","year":"2010","journal-title":"Acta Orthop Belg."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1209-14","DOI":"10.1016\/j.jhsa.2013.03.036","article-title":"The impact of Dupuytren disease on patient activity and quality of life.","volume":"38","author":"J Wilburn","year":"2013","journal-title":"J Hand Surg Am."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"397-400","DOI":"10.1136\/bmj.332.7538.397","article-title":"Dupuytren's contracture unfolded.","volume":"332","author":"W Townley","year":"2006","journal-title":"BMJ."},{"key":"ref-9","article-title":"Dupuytren's disease. British Society for Surgery of the Hand","year":"2012"},{"key":"ref-10","article-title":"Interventional procedures overview of needle fasciotomy for Dupuytren's contracture","year":"2003"},{"key":"ref-11","article-title":"Needle fasciotomy for Dupuytren's contracture. Interventional procedure guidance","year":"2004"},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"171-6","DOI":"10.1177\/1753193414535720","article-title":"Genetic and environmental influences in Dupuytren's disease: a study of 30,330 Danish twin pairs.","volume":"40","author":"S Larsen","year":"2015","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"307-17","DOI":"10.1056\/NEJMoa1101029","article-title":"Wnt signaling and Dupuytren's disease.","volume":"365","author":"G Dolmans","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"562-7","DOI":"10.1097\/BOR.0b013e32834b3309","article-title":"\u03b2-catenin signaling: a novel mediator of fibrosis and potential therapeutic target.","volume":"23","author":"A Lam","year":"2011","journal-title":"Curr Opin Rheumatol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e0158101","DOI":"10.1371\/journal.pone.0158101","article-title":"Meta-Analysis of Genome-Wide Association Studies and Network Analysis-Based Integration with Gene Expression Data Identify New Suggestive Loci and Unravel a Wnt-Centric Network Associated with Dupuytren\u2019s Disease.","volume":"11","author":"K Becker","year":"2016","journal-title":"PLoS One."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"33-40","DOI":"10.1007\/s12079-015-0312-8","article-title":"Further evidence of the involvement of the Wnt signaling pathway in Dupuytren's disease.","volume":"10","author":"E Ten Dam","year":"2016","journal-title":"J Cell Commun Signal."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"417-27","DOI":"10.1016\/j.ajhg.2017.08.006","article-title":"A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.","volume":"101","author":"M Ng","year":"2017","journal-title":"Am J Hum Genet."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"3329-41","DOI":"10.1089\/ten.tea.2009.0739","article-title":"Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury.","volume":"16","author":"K Matsushima","year":"2010","journal-title":"Tissue Eng Part A."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2373-84","DOI":"10.1681\/ASN.2004110949","article-title":"Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis.","volume":"16","author":"K Surendran","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"107-35","DOI":"10.1146\/annurev-immunol-032712-095937","article-title":"The immunology of fibrosis.","volume":"31","author":"G Wick","year":"2013","journal-title":"Annu Rev Immunol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1028-40","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease.","volume":"18","author":"T Wynn","year":"2012","journal-title":"Nat Med."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"E928-37","DOI":"10.1073\/pnas.1301100110","article-title":"Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.","volume":"110","author":"L Verjee","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"267-71","DOI":"10.1016\/0266-7681(91)90051-O","article-title":"An investigation into the role of inflammatory cells in Dupuytren\u2019s disease.","volume":"16","author":"J Andrew","year":"2016","journal-title":"J Hand Surg Br."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1622-3","DOI":"10.1016\/0140-6736(93)90760-E","article-title":"T-cell-mediated response in Dupuytren's disease.","volume":"341","author":"K Baird","year":"1993","journal-title":"Lancet."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"362-7","DOI":"10.1054\/jhsb.2000.0518","article-title":"Langerhans cells in Dupuytren's contracture.","volume":"26","author":"F Qureshi","year":"2001","journal-title":"J Hand Surg Br."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"171-9","DOI":"10.3109\/2000656X.2016.1140054","article-title":"Characterisation of the inflammatory response in Dupuytren\u2019s disease.","volume":"50","author":"C Mayerl","year":"2016","journal-title":"J Plast Surg Hand Surg."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"241-50","DOI":"10.1007\/s11552-009-9255-y","article-title":"Role of the HLA System in the Pathogenesis of Dupuytren's Disease.","volume":"5","author":"S McCarty","year":"2010","journal-title":"Hand (N Y)."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"711-20","DOI":"10.1042\/CS20150088","article-title":"Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?","volume":"129","author":"E Bianchi","year":"2015","journal-title":"Clin Sci (Lond)."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.12688\/wellcomeopenres.11466.1","article-title":"Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren\u2019s disease, with an embedded dose response study. [version 1; referees: 1 approved, 1 approved with reservations].","volume":"2","author":"J Nanchahal","year":"2017","journal-title":"Wellcome Open Res."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"282-8","DOI":"10.1016\/j.ebiom.2018.06.022","article-title":"Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.","volume":"33","author":"J Nanchahal","year":"2018","journal-title":"EBioMedicine."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"540-8","DOI":"10.1038\/ncb3336","article-title":"Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity.","volume":"18","author":"A Elosegui-Artola","year":"2016","journal-title":"Nat Cell Biol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13069-016-0046-0","article-title":"Matrix and cell phenotype differences in Dupuytren's disease.","volume":"9","author":"M van Beuge","year":"2016","journal-title":"Fibrogenesis Tissue Repair."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1785-94","DOI":"10.1016\/j.jhsa.2009.08.005","article-title":"Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture.","volume":"34","author":"L Verjee","year":"2009","journal-title":"J Hand Surg Am."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1755-8794-1-10","article-title":"Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture.","volume":"1","author":"L Satish","year":"2008","journal-title":"BMC Med Genomics."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2474-10-72","article-title":"Type-1 Collagen differentially alters beta-catenin accumulation in primary Dupuytren's Disease cord and adjacent palmar fascia cells.","volume":"10","author":"L Vi","year":"2009","journal-title":"BMC Musculoskelet Disord."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1453-9","DOI":"10.1007\/s00402-008-0726-3","article-title":"Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease.","volume":"129","author":"D Ulrich","year":"2009","journal-title":"Arch Orthop Trauma Surg."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"349-63","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling.","volume":"3","author":"J Tomasek","year":"2002","journal-title":"Nat Rev Mol Cell Biol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"1369-78","DOI":"10.1172\/JCI200112373","article-title":"DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells.","volume":"108","author":"E Olaso","year":"2001","journal-title":"J Clin Invest."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"2894-904","DOI":"10.1016\/j.ajpath.2011.09.002","article-title":"Loss of discoidin domain receptor 2 promotes hepatic fibrosis after chronic carbon tetrachloride through altered paracrine interactions between hepatic stellate cells and liver-associated macrophages.","volume":"179","author":"E Olaso","year":"2011","journal-title":"Am J Pathol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1734-44","DOI":"10.1038\/mt.2016.109","article-title":"Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofibroblast Activation and Neovessel Formation During Pulmonary Fibrosis.","volume":"24","author":"H Zhao","year":"2016","journal-title":"Mol Ther."},{"key":"ref-41","doi-asserted-by":"crossref","first-page":"907-8","DOI":"10.1302\/0301-620X.80B5.8464","article-title":"Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.","volume":"80","author":"J Hutchinson","year":"1998","journal-title":"J Bone Joint Surg Br."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"897-905","DOI":"10.1016\/j.bbadis.2012.02.001","article-title":"MMP-14 and MMP-2 are key metalloproteases in Dupuytren's disease fibroblast-mediated contraction.","volume":"1822","author":"J Wilkinson","year":"2012","journal-title":"Biochim Biophys Acta."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1160-7","DOI":"10.1016\/j.jhsa.2008.04.002","article-title":"Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease.","volume":"33","author":"P Johnston","year":"2008","journal-title":"J Hand Surg Am."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"L344-L357","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.","volume":"308","author":"F Liu","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"884-90","DOI":"10.1016\/j.bbadis.2013.02.007","article-title":"Tissue mechanics and fibrosis.","volume":"1832","author":"R Wells","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"64-76","DOI":"10.1016\/j.matbio.2017.12.004","article-title":"Matrix biomechanics and dynamics in pulmonary fibrosis.","volume":"73","author":"A Haak","year":"2018","journal-title":"Matrix Biol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"179-83","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction.","volume":"474","author":"S Dupont","year":"2011","journal-title":"Nature."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"3326-37","DOI":"10.1016\/j.ajpath.2015.08.011","article-title":"YAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased Fibroblasts.","volume":"185","author":"B Piersma","year":"2015","journal-title":"Am J Pathol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"C277-C285","DOI":"10.1152\/ajpcell.00205.2016","article-title":"TAZ activation drives fibroblast spheroid growth, expression of profibrotic paracrine signals, and context-dependent ECM gene expression.","volume":"312","author":"A Jorgenson","year":"2017","journal-title":"Am J Physiol Cell Physiol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"493-6","DOI":"10.1177\/1753193409103729","article-title":"Histological staging and Dupuytren's disease recurrence or extension after surgical treatment: a retrospective study of 124 patients.","volume":"34","author":"T Balaguer","year":"2009","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12891-016-1200-y","article-title":"Systematic review of non-surgical treatments for early dupuytren's disease.","volume":"17","author":"C Ball","year":"2016","journal-title":"BMC Musculoskelet Disord."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"149-58","DOI":"10.1093\/bmb\/ldw020","article-title":"Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.","volume":"118","author":"F Smeraglia","year":"2016","journal-title":"Br Med Bull."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"968-79","DOI":"10.1056\/NEJMoa0810866","article-title":"Injectable collagenase clostridium histolyticum for Dupuytren's contracture.","volume":"361","author":"L Hurst","year":"2009","journal-title":"N Engl J Med."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"2370-6","DOI":"10.1016\/j.jhsa.2013.08.114","article-title":"Collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice.","volume":"38","author":"C Peimer","year":"2013","journal-title":"J Hand Surg Am."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"141-9","DOI":"10.1177\/1753193414528843","article-title":"Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture.","volume":"40","author":"C Peimer","year":"2015","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"1079-86","DOI":"10.2106\/JBJS.17.01128","article-title":"Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up.","volume":"100","author":"J Str\u00f6mberg","year":"2018","journal-title":"J Bone Joint Surg Am."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"841-7","DOI":"10.1177\/1753193418790157","article-title":"Five-year results after collagenase treatment of Dupuytren disease.","volume":"43","author":"J Werlinrud","year":"2018","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhsa.2018.10.002","article-title":"Durability of Collagenase Treatment for Dupuytren Disease of the Thumb and First Web After at Least 2 Years' Follow-Up.","author":"L Steenbeek","year":"2018","journal-title":"J Hand Surg Am."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"2027-2038.e1","DOI":"10.1016\/j.jhsa.2010.08.007","article-title":"Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.","volume":"35","author":"D Gilpin","year":"2010","journal-title":"J Hand Surg Am."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"767-74","DOI":"10.1016\/j.jhsa.2007.04.002","article-title":"Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture.","volume":"32","author":"M Badalamente","year":"2007","journal-title":"J Hand Surg Am."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"e004166","DOI":"10.1136\/bmjopen-2013-004166","article-title":"Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren's contracture: a retrospective cohort study.","volume":"4","author":"I Atroshi","year":"2014","journal-title":"BMJ Open."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1826-1834.e32","DOI":"10.1016\/j.jhsa.2011.08.004","article-title":"Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture.","volume":"36","author":"N Chen","year":"2011","journal-title":"J Hand Surg Am."},{"key":"ref-63","article-title":"Dupuytren's interventions surgery vs collagenase","year":"2018"},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"178-87","DOI":"10.1097\/01.bth.0000186794.90431.a4","article-title":"A review of common practice in Dupuytren surgery.","volume":"9","author":"I Au-Yong","year":"2005","journal-title":"Tech Hand Up Extrem Surg."},{"key":"ref-65","doi-asserted-by":"crossref","first-page":"90-4","DOI":"10.1302\/0301-620X.82B1.9808","article-title":"Dermofasciectomy in the management of Dupuytren's disease.","volume":"82","author":"J Armstrong","year":"2000","journal-title":"J Bone Joint Surg Br."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"e0164849","DOI":"10.1371\/journal.pone.0164849","article-title":"Recurrence of Dupuytren's contracture: A consensus-based definition.","volume":"12","author":"H Kan","year":"2017","journal-title":"PLoS One."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"440-3","DOI":"10.1016\/0007-1226(94)90075-2","article-title":"Long term follow-up of dermofasciectomy for Dupuytren's contracture.","volume":"47","author":"T Brotherston","year":"1994","journal-title":"Br J Plast Surg."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"563-6","DOI":"10.1016\/J.JHSB.2005.07.001","article-title":"Recurrence after surgery for Dupuytren's disease: a randomized trial of two skin incisions.","volume":"30","author":"N Citron","year":"2005","journal-title":"J Hand Surg Br."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"469-77","DOI":"10.1097\/PRS.0b013e31823aea95","article-title":"Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy.","volume":"129","author":"A van Rijssen","year":"2012","journal-title":"Plast Reconstr Surg."},{"key":"ref-70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010143.pub2","article-title":"Surgery for Dupuytren's contracture of the fingers.","author":"J Rodrigues","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"717-25","DOI":"10.1016\/j.jhsa.2006.02.021","article-title":"A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study.","volume":"31","author":"A van Rijssen","year":"2006","journal-title":"J Hand Surg Am."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"7-17","DOI":"10.1177\/1753193416660045","article-title":"Functional outcome and complications following surgery for Dupuytren's disease: a multi-centre cross-sectional study.","volume":"42","author":"J Rodrigues","year":"2017","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"2095-2105.e7","DOI":"10.1016\/j.jhsa.2012.06.032","article-title":"Correction of contracture and recurrence rates of Dupuytren contracture following invasive treatment: the importance of clear definitions.","volume":"37","author":"P Werker","year":"2012","journal-title":"J Hand Surg Am."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"283-9","DOI":"10.1016\/j.bjps.2017.11.015","article-title":"Outcome measurement in plastic surgery.","volume":"71","author":"J Wormald","year":"2018","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2474-14-131","article-title":"Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.","volume":"14","author":"C Ball","year":"2013","journal-title":"BMC Musculoskelet Disord."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"441-4","DOI":"10.1016\/j.jbspin.2014.01.007","article-title":"URAM scale for functional assessment in Dupuytren's disease: a comparative study of its properties.","volume":"81","author":"B Bernab\u00e9","year":"2014","journal-title":"Joint Bone Spine."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"301-9","DOI":"10.1177\/1753193416677712","article-title":"Recovery, responsiveness and interpretability of patient-reported outcome measures after surgery for Dupuytren's disease.","volume":"42","author":"J Rodrigues","year":"2017","journal-title":"J Hand Surg Eur Vol."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/1471-2474-15-361","article-title":"Psychometric evaluation of the Disabilities of the Arm, Shoulder and Hand (DASH) with Dupuytren's contracture: validity evidence using Rasch modeling.","volume":"15","author":"N Forget","year":"2014","journal-title":"BMC Musculoskelet Disord."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-231\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-231\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-231\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T20:17:46Z","timestamp":1663013866000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-231\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":78,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17779.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.19439.r44720","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.19439.r44719","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.19439.r44718","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-231\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.19439.r44719, Gary M Pess, Central Jersey Hand Surgery, New Jersey, USA, 28 Feb 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-231\/v1#referee-response-44719","order":0,"name":"referee-response-44719","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.19439.r44720, David Warwick, University of Southampton, Southampton, UK, 28 Feb 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-231\/v1#referee-response-44720","order":1,"name":"referee-response-44720","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.19439.r44718, Isam Atroshi, Department of Clinical Sciences and Department of Orthopaedics, Lund University, Lund, Sweden, 28 Feb 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-231\/v1#referee-response-44718","order":2,"name":"referee-response-44718","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}